AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1 – 88. (cancelled)

89. (Currently Amended) A method of treatment for an allergic disease~~regulating immune response without systemic pharmacological activity~~ comprising topically administering to a patient in need an effective amount of a medicament containing an adenine compound represented by a general formula (1):



wherein

Ring A is a 6 to 10 membered mono- or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono- or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is a single bond, or alkylene which may be substituted by oxo group, ~~or divalent group of the formula below:~~



~~(wherein r^1 and r^2 are independently an integer selected from 1 to 3),~~

Y^2 is a single bond, or alkylene, ~~optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 or 2 oxygen atoms, or divalent group of the formula below:~~



~~(wherein A' is cycloalkylene, s^1 is an integer selected from 1 to 3),~~

Z is alkylene,

Q^1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q^2 is a group selected from the group consisting of Substituents set forth below,

~~R^{10} or R^{11} in Q^2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,~~

when m is 0, Q^1 is a group selected from the group consisting of Substituents set forth below,

Substituents: $-COOR^{10}$; $-COSR^{10}$; ~~$-OCOOR^{10}$; $-OCOR^{10}$; $-CONR^{11}R^{12}$; $-OCONR^{11}R^{12}$~~

(wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, ~~R^{11} and R^{12} are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R^{11} and R^{12} may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)~~);

~~and any group selected from the following formulas (3) - (6):~~



(3) (4) (5) (6)

~~(wherein M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3),~~

and when m is 2, the groups (Y^2-Q^2) may be the same or different,

or a pharmaceutically acceptable salt thereof as an active ingredient and wherein said medicament shows an effect only at the applied location.

90. (Currently Amended) The method according to claim 89 wherein the adenine compound is represented by a general formula (1):



wherein

Ring A is a 6 to 10 membered mono or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, m is an integer selected from 0 ~~to 2~~or 1,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is a single bond, or alkylene which may be substituted by oxo group, ~~or divalent group of the formula below:~~



~~(wherein r^1 and r^2 are independently an integer selected from 1 to 3),~~

Y^2 is a single bond, or alkylene ~~optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 or 2 oxygen atoms, or divalent group of the formula below:~~



~~(wherein A' is cycloalkylene, s^1 is an integer selected from 1 to 3)~~,

Z is alkylene,

Q^1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q^2 is a group selected from the group consisting of Substituents set forth below,

~~R^{10} or R^{11} in Q^2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,~~

when m is 0, Q^1 is a group selected from the group consisting of Substituents set forth below,

Substituents: $-COOR^{10}$; $-COSR^{10}$; ~~$-OCOOR^{10}$; $-OCOR^{10}$; and $-CONR^{11}R^{12}$;~~

(wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkeny group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group~~, R^{11} and R^{12} are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R^{11} and R^{12} may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)~~));

~~and when m is 2, the groups (Y^2-Q^2) may be the same or different,~~

or a pharmaceutically acceptable salt thereof as an active ingredient

and wherein said medicament shows an effect only at the applied location.

91. (Currently Amended) The method according to claim 90, wherein in the general formula (1), the substituent(s), by which alkyl group, alkenyl group or alkynyl group in R^{10}, ~~R^{11} and R^{12}~~ is substituted, are the same or different and at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.

92. (Previously Presented) The method according to claim 90, wherein in the general formula (1), Z is methylene and Ring A is benzene.

93. (Previously Presented) The method according to claim 90, wherein in the general formula (1), Y^1 is C_{1-5} alkylene, Q^1 is hydrogen atom, hydroxy group or alkoxy group, Y^2 is a single bond, and Q^2 is $-COOR^{10}$.

94. (Previously Presented) The method according to claim 90, wherein in the general formula (1), Z is methylene, Ring A is benzene, R^{10} is alkyl group substituted by hydroxy group, amino group, alkylamino group or dialkylamino group, and m is 1.

95. (Previously Presented) The method according to claim 90, wherein in the general formula (1), $Y^1$is C_{1-5} alkylene, Q^1 is hydrogen atom, hydroxy group or alkoxy group, Y^2 is C_{1-3} alkylene, Q^2 is $-COOR^{10}$, and m is 1.

96. (Currently Amended) The method according to claim 90, wherein in the general formula (1), m is 0, Y^1 is C_{1-6} alkylene which may be substituted with oxo group, and Q^1 is $-COOR^{10}$, ~~$-COSR^{10}$, $-OCOR^{10}$, $-OCOOR^{10}$, $-CONR^{11}R^{12}$ or $-OCONR^{11}R^{12}$~~.

97. (Previously Presented) The method according to claim 90, wherein in the general formula (1), and X^1 is oxygen atom, sulfur atom or NR^1 (wherein R^1 is hydrogen atom or alkyl group).

98. (Previously Presented) The method according to claim 90, wherein in the general formula (1), m is 0, X^1 is a single bond, Y^1 is C_{1-4} alkylene which may be substituted by oxo group, and Q^1 is $-COOR^{10}$.

99. (Previously Presented) The method according to claim 90, wherein in the general formula (1), either 1) or 2) below obtains:

1) n is 0;

2) n is 1 or 2, and R is alkyl group, alkoxy group or halogen atom.

100. (Previously Presented) An adenine compound represented by a general formula (1):



wherein

Ring A is a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is a single bond, alkylene which may be substituted by oxo group, or divalent group of the formula below:



(wherein r^1 and r^2 are independently an integer selected from 1 to 3),

Y^2 is a single bond, alkylene optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 or 2 oxygen atoms, or divalent group of the formula below:



(wherein A' is cycloalkylene, s^1 is an integer selected from 1 to 3),

Z is methylene,

Q^1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q^2 is a group selected from the group consisting of Substituents set forth below,

R^{10} or R^{11} in Q^2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,

when m is 0, Q^1 is a group selected from the group consisting of Substituents set forth below,

Substituents: $-COOR^{10}$; $-COSR^{10}$; $-OCOOR^{10}$; $-OCOR^{10}$; $-CONR^{11}R^{12}$; $-OCONR^{11}R^{12}$

(wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkeny group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R^{11} and R^{12} are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R^{11} and R^{12} may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s));

and any group selected from the following formulas (3) - (6):



(3) (4) (5) (6)

(wherein M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3),

and when m is 2, the groups (Y^2-Q^2) may be the same or different,

its tautomer or its pharmaceutically acceptable salt.

101. (Previously Presented) The adenine compound, its tautomer or its pharmaceutically acceptable salt according to claim 100, wherein in the general formula (1), the heteroaromatic ring in Ring A is furan, thiophene, or pyridine.

102. (Previously Presented) The adenine compound or its pharmaceutically acceptable salt according to claim 100, wherein in the general formula (1), Q^1 is hydrogen atom, hydroxy group or alkoxy group, Y^1 is $C_{1\text{-}5}$ alkylene, Q^2 is -$COOR^{10}$ (wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group), and m is 1.

103. (Previously Presented) The adenine compound, its tautomer or its pharmaceutically acceptable salt according to claim 100, wherein in the general formula (1), Y^2 is a single bond.

104. (Currently Amended) The adenine compound, its tautomer or its pharmaceutically acceptable salt ~~according to claim 100~~, of formula (I)



wherein ~~in the general formula (1),~~

Ring A is a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

(wherein r^1 and r^2 are independently an integer selected from 1 to 3),

Z is methylene,

m is 0, $Y^1$is C_{1-6} alkylene which may be substituted by oxo group, and Q^1 is $-COOR^{10}$, $-COSR^{10}$, $-OCOR^{10}$, $-OCOOR^{10}$, $-CONR^{11}R^{12}$ or $-OCONR^{11}R^{12}$ (wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R^{11} and R^{12} are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R^{11} and R^{12} may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s));

and any group selected from the following formulas (3) - (6):



(3) (4) (5) (6)

(wherein M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3).

105. (Previously Presented) The adenine compound or its pharmaceutically acceptable salt according to claim 100, wherein in the general formula (1), the substituent(s) by which alkyl group, alkeny group or alkynyl group in R^{10}, R^{11}, R^{12}, R^{20}, R^{21} and R^{22} is substituted, are at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.

106. (Currently Amended) The adenine compound, its tautomer or its pharmaceutically acceptable salt according to claim 100, wherein R is ~~hydrogen atom,~~ alkyl group, alkoxy group, or halogen atom.

107. (Previously Presented) An adenine compound represented by a general formula (1):



wherein

Ring A is benzene,

n is an integer selected from 0 to 2, m is 1,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is C_{1-5} alkylene,

Y^2 is a single bond,

Z is methylene,

Q^1 is hydrogen atom, hydroxy group or alkoxy group,

Q^2 is $-COOR^{23}$ (wherein R^{23} is alkyl group substituted by amino group, alkylamino group or dialkylamino group),

and m is 1,

its tautomer or a pharmaceutically acceptable salt thereof as an active ingredient.

108. (Currently Amended) The adenine compound, its tautomer, or its pharmaceutically acceptable salt according to claim 100 or 107, wherein in the general formula (1), X^1 is oxygen atom, sulfur atom or NR^1 (wherein R^1 is hydrogen atom or alkyl group).

109. (Cancelled)

110. (Previously Presented) The method according to ~~claim 109~~claims 89 or 90 wherein the allergic disease is asthma or atopic dermatosis.

111. (Currently Amended) The method according to claim 90, wherein the half-life in serum without hemocytes and blood coagulation factor of ~~on~~ the compound of the general formula (1) is less than 1 hour.

112. (Previously Presented) The method according to claim 90, wherein the half-life in liver S9 on the compound of the general formula (1) is less than 1 hour.

113. (Previously Presented) The method according to claim 90, wherein the medicament is an inhalation formulation.

114. (Previously Presented) A method for regulating immune response, comprising topically administering to a patient in need an effective amount of an adenine compound of claim 100 or 107.

115. (Currently Amended) A method for treatment ~~or prophylaxis~~ of an allergic disease ~~allergic diseases without systemic pharmacological activity~~, comprising topically administering to a patient in need an effective amount of a medicament containing an adenine compound of claim 100 or 107, and wherein said medicament shows an effect only at the applied location.

116. (Previously Presented) The method according to claim 115, wherein the allergic disease is asthma or atopic dermatosis.

117. (Currently Amended) The method according to claim 115, wherein the half-life of the compound of the formula (1) in serum without hemocytes and blood coagulation factor ~~serum of the compound of the formula (1)~~ is less than 1 hour.

118. (Previously Presented) The method according to claim 115, wherein the half-life in liver S9 on the compound of the formula (1) is less than 1 hour.

119. (Previously Presented) The method according to claim 115, wherein the medicament is administered by inhalation.

120. (Currently Amended) A compound selected from the group consisting of:

2-Butoxy-8-hydroxy-9-(5-methoxycarbonylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-(5-isopropoxycarbonylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-{(6-methoxycarbonyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(6-isopropoxycarbonyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{6-(4-ethoxycarbonyl-1-piperidyl)-3-pyridylmethyl} adenine,

2-Butoxy-8-hydroxy-9-{6-(3-ethoxycarbonyl-1-piperidyl)-3-pyridylmethyl} adenine,

2-Butoxy-8-hydroxy-9-{(6-ethoxycarbonylmethoxy-2-naphthyl)methyl} adenine),

2-Butylamino-8-hydroxy-9-(5-ethoxycarbonylfurfuryl)adenine,

8-Hydroxy-2-methoxycarbonylmethylamino-9-{(6-methyl-3-pyridyl)methyl} adenine,

2-(2-Acetoxyethylamino)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-2-(2-methoxycarbonyloxyethylamino)-9-{(6-methyl-3-pyridyl) methyl}adenine,

2-(2-Acetoxyethoxy)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-9-(6-methyl-3-pyridyl)methyl-2-{2-(propionyloxy)ethoxy} adenine,

2-{2-(Methoxycarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl) methyl}adenine,

2-{2-(N,N-Dimethylaminocarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-9-{(6-methyl-3-pyridyl)methyl}-2-{(2-oxo-1,3-dioxolan-4-yl) methylamino}adenine,

8-Hydroxy-2-methoxycarbonylethyl-9-{(6-methyl-3-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{4-(S-methylthiocarbonyl)methylbenzyl}adenine,

2-Butoxy-9-{4-(S-ethylthiocarbonyl)methylbenzyl}-8-hydroxyadenine,

~~2-Butoxy-8-hydroxy-9-(4-carbamoylinethylbenzyl)adenine~~2-Butoxy-8-hydroxy-9-(4-carbamoylmethylbenzyl)adenine,

2-Butoxy-8-hydroxy-9-(4-methylcarbamoylmethylbenzyl)adenine,

2-Butoxy-8-hydroxy-9-(4-dimethylcarbamoylmethylbenzyl)adenine,

2-Butoxy-8-hydroxy-9-(4-morpholinomethylbenzyl)adenine,

2-Butoxy-8-hydroxy-9-(5-methoxycarbonylmethylfurfuryl)adenine,

2-Butoxy-8-hydroxy-9-{(6-S-methylthiocarbonyl-3-pyridyl)methyl}adenine,

2-Butoxy-9-{(6-carbamoyl-3-pyridyl)methyl}-8-hydroxyadenine,

2-Butoxy-8-hydroxy-9-{6-(4-methoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine,

2-Butoxy-8-hydroxy-9-{6-(3-methoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine,

2-Butoxy-8-hydroxy-9-{(6-methoxycarbonylmethoxy-2-naphthyl)methyl} adenine,

2-Butoxy-8-hydroxy-9-{(6-methoxycarbonylmethyl-3-pyridyl)methyl}adenine,

2-Butoxy-9-{6-(γ-butyrolactonyl)thio-3-pyridyl}methyl}-8-hydroxyadenine,

2-Butoxy-8-hydroxy-9-{(2-methoxycarbonyl-4-pyridyl)methyl}adenine,

2-Butoxy-8-hydroxy-9-{(5-methoxycarbonyl-2-thienyl)methyl}adenine, and

2-Butoxy-8-hydroxy-9-{(5-methoxycarbonylmethyl-3-pyridyl)methyl}adenine.

121. (New) A method of locally raising interferon levels in a patient comprising topically administering to the patient in need an effective amount of a medicament containing an adenine compound represented by a general formula (1):



wherein

Ring A is a 6 to 10 membered mono- or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono- or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is a single bond, or alkylene which may be substituted by oxo group,

Z is alkylene,

Q^1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q^2 is a group selected from the group consisting of Substituents set forth below,

when m is 0, Q^1 is a group selected from the group consisting of Substituents set forth below,

Substituents: $-COOR^{10}$; $-COSR^{10}$;

and when m is 2, the groups (Y^2-Q^2) may be the same or different,

or a pharmaceutically acceptable salt thereof as an active ingredient and wherein said medicament raises interferon level locally and does not raise interferon levels when administered orally.

122. (New) An adenine compound represented by a general formula (1):



wherein

Ring A is a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom,

n is an integer selected from 0 to 2, m is an integer selected from 0 or 1,

R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,

X^1 is oxygen atom, sulfur atom, NR^1 (wherein R^1 is hydrogen atom or alkyl group) or a single bond,

Y^1 is a single bond, or alkylene which may be substituted by oxo group,

Y^2 is a single bond, or alkylene,

Z is methylene,

Q^1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents set forth below,

Q^2 is a group selected from the group consisting of Substituents set forth below,

when m is 0, Q^1 is a group selected from the group consisting of Substituents set forth below,

Substituents: $-COOR^{10}$; $-COSR^{10}$;

wherein R^{10} is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkeny group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group,

its tautomer or its pharmaceutically acceptable salt.

123. (New) The adenine compound according to claim 9122, wherein in the general formula (1), the substituent(s), by which alkyl group, alkenyl group or alkynyl group in R^{10} is substituted, are the same or different and at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.

124. (New) The adenine compound according to claim 122, wherein in the general formula (1), Ring A is pyridine.

125. (New) The adenine compound according to claim 122, wherein in the general formula (1), Y^1 is C_{1-5} alkylene, Q^1 is hydrogen atom, hydroxy group or alkoxy group, Y^2 is a single bond, and Q^2 is $-COOR^{10}$.

126. (New) The adenine compound according to claim 122, wherein in the general formula (1), R^{10} is alkyl group substituted by hydroxy group, amino group, alkylamino group or dialkylamino group, and m is 1.

127. (New) The adenine compound according to claim 122, wherein in the general formula (1), $Y^1$is C_{1-5} alkylene, Q^1 is hydrogen atom, hydroxy group or alkoxy group, Y^2 is C_{1-3} alkylene, Q^2 is -$COOR^{10}$, and m is 1.

128. (New) The adenine compound according to claim 122, wherein in the general formula (1), m is 0, Y^1 is C_{1-6} alkylene which may be substituted with oxo group, and Q^1 is -$COOR^{10}$.

129. (New) The adenine compound according to claim 122, wherein in the general formula (1), and X^1 is oxygen atom, sulfur atom or NR^1 (wherein R^1 is hydrogen atom or alkyl group).

130. (New) The adenine compound according to claim 122, wherein in the general formula (1), m is 0, X^1 is a single bond, Y^1 is C_{1-4} alkylene which may be substituted by oxo group, and Q^1 is -$COOR^{10}$.

131. (New) The adenine compound according to claim 122, wherein in the general formula (1), either 1) or 2) below obtains:

1) n is 0;

2) n is 1 or 2, and R is alkyl group, alkoxy group or halogen atom.

132. (New) 120. (Currently Amended) A compound selected from the group consisting of:

8-Hydroxy-2-methoxycarbonylmethylamino-9-{(6-methyl-3-pyridyl)methyl} adenine,

2-(2-Acetoxyethylamino)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-2-(2-methoxycarbonyloxyethylamino)-9-{(6-methyl-3-pyridyl) methyl}adenine,

2-(2-Acetoxyethoxy)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-9-(6-methyl-3-pyridyl)methyl-2-{2-(propionyloxy)ethoxy} adenine,

2-{2-(Methoxycarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl) methyl}adenine,

2-{2-(N,N-Dimethylaminocarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine,

8-Hydroxy-9-{(6-methyl-3-pyridyl)methyl}-2-{(2-oxo-1,3-dioxolan-4-yl) methylamino}adenine, and

8-Hydroxy-2-methoxycarbonylethyl-9-{(6-methyl-3-pyridyl)methyl}adenine.